Genetic contributions to glucose intolerance in polycystic ovary syndrome

Reproductive BioMedicine Online

Volumn 9, Issue 1, 2004, Pages 28-34

  Ehrmann, David A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Diabetes; Endocrine disorder; Genetics; Glucose intolerance; Insulin resistance; PCOS

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; COMPLEMENTARY DNA; CORTISONE ACETATE; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; TROGLITAZONE;

CLINICAL FEATURE; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETIC IDENTIFICATION; GENETIC PREDISPOSITION; GLUCOSE INTOLERANCE; HEREDITY; HIGH RISK PATIENT; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; MULTIFACTORIAL INHERITANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PANCREAS ISLET BETA CELL; PATHOGENESIS; PHENOTYPE; REVIEW;

EID: 3242680659     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)62106-2     Document Type: Article

References (69)

1. Almind K, Bjorbaek C, Vestergaard H et al. 1993 Amino acid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus. Lancet 342, 828-832.
2. Almind K, Inoue G, Pedersen O et al. 1996 A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. Journal of Clinical Investigation 97, 2569-2575.
3. Arslanian SA, Lewy VD, Danadian K 2001 Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and β-cell dysfunction and risk of cardiovascular disease. Journal of Clinical Endocrinology and Metabolism 86, 66-71.
4. Azziz R, Kashar-Miller MD 2000 Family history as a risk factor for the polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism 13, 1303-1306.
5. Bentley-Lewis R, Legro R, Wang S et al. 2000 Clustering of insulin resistance and lipoprotein changes in polycystic ovary syndrome (PCOS) families - co-segregation with hyperandrogenemia rather than anovulation. Endocrine Society's 82nd Annual Meeting, 2000 June 21-24, 2000, Toronto, Ontario.
6. Bergman R, Phillips L, Cobelli C 1981 Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. Journal of Clinical Investigation 68, 1456-1467.
7. Burks DJ, White MF 2001 IRS proteins and β-cell function. Diabetes 50, S140-145.
8. Cavaghan MK, Ehrmann DA, Byrne MM et al. 1997 Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. Journal of Clinical Investigation 100, 530-537.
9. Clausen J, Hansen T, Bjorbaek C et al. 1995 Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1. Lancet 346, 397-402.
10. Coderre L, Srivastava AK, Chiasson JL 1992a Effect of hypercorticism on regulation of skeletal muscle glycogen metabolism by insulin. American of Journal Physiology 262, E427-433.
11. Coderre L, Srivastava AK, Chiasson JL 1992b Effect of hypercorticism on regulation of skeletal muscle glycogen metabolism by epinephrine. American Journal of Physiology 262, E434-439.
12. Colilla S, Cox N, Ehrmann D 2001 Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first-degree relatives. Journal of Clinical Endocrinology and Metabolism 86, 1626-1632.
13. Dahlgren E, Janson PO, Johansson A et al. 1992 Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertility and Sterility 57, 505-513.
14. Dunaif A 1997 Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews 18, 774-800.
15. Dunaif A, Finegood DT 1996 β-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 81, 942-947.
16. Dunaif A, Graf M, Mandeli J et al. 1987 Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance and/or hyperinsulinemia. Journal of Clinical Endocrinology and Metabolism 65, 499-507.
17. Dunaif A, Segal K, Futterweit W et al. 1989 Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38, 1165-1174.
18. Dunaif A, Xia J, Book C et al. 1995 Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle: a potential mechanism for insulin resistance in the polycystic ovary syndrome. Journal of Clinical Investigation 96, 801-810.
19. Edelstein S, Knowler W, Bain R et al. 1997 Predictors of progression from impaired glucose tolerance to NIDDM. Diabetes 46, 701-710.
20. Ehrmann D, Rosenfield R, Barnes R et al. 1992 Detection of functional ovarian hyperandrogenism in women with androgen excess. New England Journal of Medicine 327, 157-162.
21. Ehrmann D, Barnes R, Rosenfield R 1995a Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocrine Reviews 16, 322-353.
22. Ehrmann DA, Sturis J, Byrne MM et al. 1995b Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. Journal Clinical Investigation 96, 520-527.
23. Ehrmann D, Schneider D, Sobel B et al. 1997 Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 82, 2108-2116.
24. Ehrmann D, Barnes R, Rosenfield R et al. 1999 Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22, 141-146.
25. Ehrmann DA, Schwarz PE, Hara M et al. 2002 Relationship of calpain-10 genotype to phenotypic features of polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 87, 1669-1673.
26. Ehrmann DA, Breda E, Corcoran MC et al. 2003 Impaired β-cell compensation to dexamethasone-induced hyperglycemia in women with polycystic ovary syndrome. American Journal of Physiology Endocrinology and Metabolism Dec 16, Epub Dec 09.
27. El Mkadem SA, Lautier C, Macari F et al. 2001 Role of allelic variants Gly972Arg of IRS-1 and Gly1057Asp of IRS-2 in moderate-to-severe insulin resistance of women with polycystic ovary syndrome. Diabetes 50, 2164-2168.
28. Elbein SC, Hasstedt SJ, Wegner K et al. 1999 Heritability of pancreatic β-cell function among nondiabetic members of Caucasian familial type 2 diabetic kindreds. Journal of Clinical Endocrinology and Metabolism 84, 1398-1403.
29. Fajans S, Conn J 1954 An approach to the prediction of diabetes mellitus by modification of the glucose tolerance test with cortisone. Diabetes 3, 296-304.
30. Fauser BCMJ. 2003 Polycystic ovary syndrome - where are we today? Human Reproduction 18 (suppl. 1), Abstract 0-138.
31. Fischer B, Rausch U, Wollny P et al. 1990 Immunohistochemical localization of the glucocorticoid receptor in pancreatic β-cells of the rat. Endocrinology 126, 2635-2641.
32. Franks S, Gharani N, McCarthy M 2001 Candidate genes in polycystic ovary syndrome. Human Reproduction Update 7, 405-410.
33. Hara M, Alcoser SY, Qaadir A et al. 2002 Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene. Journal of Clinical Endocrinology and Metabolism 87, 772-775.
34. Hart L, Stolk R, Dekker J et al. 1999 Prevalence of variants in candidate genes for type 2 diabetes mellitus in The Netherlands: the Rotterdam study and the Hoorn study. Journal of Clinical Endocrinology and Metabolism 84, 1002-1006.
35. Henriksen J, Alford F, Ward G et al. 1997 Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in nondiabetic first-degree relatives of NIDDM patients. Diabetologia 40, 1439-1448.
36. Holte J, Bergh T, Berne C et al. 1994 Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. Journal of Clinical Endocrinology and Metabolism 78, 1052-1058.
37. Inzucchi S, Maggs D, Spollett G et al. 1998 Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus [see comments]. New England Journal of Medicine 338, 867-872.
38. Kahn S, Prigeon R, McCulloch D et al. 1993 Quantification of the relationship between insulin sensitivity and β-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42, 1663-1672.
39. Kahsar-Miller MD, Nixon C, Boots LR et al. 2001 Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertility and Sterility 75, 53-58.
40. Knochenhauer E, Key T, Kahsar-Miller M et al. 1998 Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. Journal of Clinical Endocrinology and Metabolism 83, 3078-3082.
41. Larsson H, Ahren B 1999 Insulin resistant subjects lack islet adaptation to short-term dexamethasone-induced reduction in insulin sensitivity. Diabetologia 42, 936-943.
42. Legro R, Driscoll D, Strauss J 3rd et al. 1998 Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proceedings of the National Academy of Sciences of the USA 95, 14956-14960.
43. Legro R, Kunselman A, Dodson W et al. 1999 Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. Journal of Clinical Endocrinology and Metabolism 84, 165-169.
44. Lillioja S, Mott D, Spraul M et al. 1993 Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. New England Journal of Medicine 329, 1988-1992.
45. Matsumoto K, Yamasaki H, Akazawa S et al. 1996 High-dose but not low-dose dexamethasone impairs glucose tolerance by inducing compensatory failure of pancreatic β-cells in normal men. Journal of Clinical Endocrinology and Metabolism 81, 2621-2626.
46. Matthes H, Kaiser A, Stier U et al. 1994 Glucocorticoid receptor gene expression in the exocrine and endocrine rat pancreas. Endocrinology 135, 476-479.
47. McMahon M, Gerich J, Rizza R 1988 Effects of glucocorticoids on carbohydrate metabolism. Diabetes/Metabolism Reviews 4, 17-30.
48. Norman RJ, Masters L, Milner CR et al. 2001 Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Human Reproduction 16, 1995-1998.
49. Ogawa A, Johnson JH, Ohneda M et al. 1992 Roles of insulin resistance and β-cell dysfunction in dexamethasone-induced diabetes. Journal of Clinical Investigation 90, 497-504.
50. O'Meara N, Blackman J, Ehrmann D et al. 1993 Defects in beta cell function and insulin action in functional ovarian hyperandrogenism. Journal of Clinical Endocrinology and Metabolism 76, 1241-1247.
51. Pimenta W, Korytkowski M, Mitrakou A et al. 1995 Pancreatic β-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative [see comments]. Journal of American Medical Association 273, 1855-1861.
52. Polonsky K, Sturis J, Bell G 1996 Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. New England Journal of Medicine 334, 777-783.
53. Polonsky K, Given B, Hirsch L et al. 1988 Abnormal patterns of insulin secretion in non-insulin dependent diabetes. New England Journal of Medicine 318, 1231-1239.
54. Porzio O, Federici M, Hribal M et al. 1999 The Gly972→Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells. Journal of Clinical Investigation 104, 357-364.
55. Saltiel A, Olefsky J 1996 Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45, 1661-1669.
56. Sir-Petermann T, Perez-Bravo F, Angel B et al. 2001 G972R polymorphism of IRS-1 in women with polycystic ovary syndrome. Diabetologia 44, 1200-1201.
57. Tappy L, Randin D, Vollenweider P et al. 1994 Mechanisms of dexamethasone-induced insulin resistance in healthy humans. Journal of Clinical Endocrinology and Metabolism 79, 1063-1069.
58. Turnbow MA, Keller SR, Rice KM et al. 1994 Dexamethasone down-regulation of insulin receptor substrate-1 in 3T3-L1 adipocytes. Journal of Biological Chemistry 269, 2516-2520.
59. Urbanek M, Legro R, Driscoll D et al. 1999 Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin [see comments]. Proceedings of the National Academy Sciences of the USA 96, 8573-8578.
60. Vamecq J, Latruffe N 1999 Medical significance of peroxisome proliferator-activated receptors. Lancet 354, 141-148.
61. Webb G, Akbar M, Zhao C et al. 2000 Expression profiling of pancreatic beta cells: glucose regulation of secretory and metabolic pathway genes. Proceedings of the National Academy of Sciences of the USA 97, 5773-5778.
62. Weyer C, Bogardus C, Mott D et al. 1999 The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Journal of Clinical Investigation 104, 787-794.
63. Willi S, Kennedy A, Wallace P et al. 1999 Troglitazone prevents glucocorticoid-induced insulin resistance in humans. 59th Scientific Session of the American Diabetes Association, San Diego, CA.
64. Witchel SF, Smith R, Tomboc M et al. 2001 Candidate gene analysis in premature pubarche and adolescent hyperandrogenism. Fertility and Sterility 75, 724-730.
65. Wood JR, Nelson VL, Ho C et al. 2003 The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis. Journal of Biological Chemistry 278, 26380-26390.
66. World Health Organization 1985 Diabetes Mellitus: Report of a WHO Study Group. WHO, Geneva (Technical Report Series, no. 727).
67. Wu X, Sallinen K, Anttila L et al. 2000 Expression of insulin-receptor substrate-1 and -2 in ovaries from women with insulin resistance and from controls. Fertility and Sterility 74, 564-572.
68. Yamasaki Y, Kawamori R, Wasada T et al. 1997 Pioglitazone (AD4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan. Tohoku Journal Experimental Medicine 183, 173-183.
69. Zawadzki J, Dunaif A 1992 Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens, J, Haseltine F, Merriam, G (eds) Polycystic Ovary Syndrome. Blackwell Scientific, Boston, MA, USA.